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Abstract: Dried flowers of Daphne genkwa Sieb. et Zucc. (Thymelaeaceae) are a Chinese 
herbal medicine used as an abortifacient with purgative, diuretic and anti-inflammatory 
activities. However, the activity of this medicine against enteroviral infections has not been 
investigated. The water-extract of dried buds of D. genkwa Sieb. et Zucc. (DGFW) was 
examined against various strains of enterovirus 71 (EV71) by neutralization assay, and its 
initial mode of action was characterized by time-of-addition assay followed by attachment 
and penetration assays. Pretreatment of DGFW with virus abolished viral replication, 
indicating that DGFW inhibits EV71 by targeting the virus. GFW exerts its anti-EV71 
effects by inhibiting viral entry without producing cytotoxic side effects and thus provides 
a potential agent for antiviral chemotherapeutics. 
Keywords: attachment assay; cytopathic effect; enterovirus 71; Daphne Genkwa Sieb. et 
Zucc.; penetration assay; yuanhua 
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1. Introduction 
Enterovirus 71 (EV71) is a positive-strand RNA virus and belongs to the Enterovirus genus of the 
family Picornaviridae. It is a member of the Picornaviridae family and has a (+)RNA genome 7.5 kb in 
length that encodes 2193 amino acids [1,2]. The polyprotein is cleaved proteolytically into distinct 
proteins by the viral-encoded proteases 2A
pro and 3C
pro. The structural proteins comprising VP1 to VP4 
and the nonstructural proteins 2A to 2C and 3A to 3D are required for viral replication [2]. EV71 is a 
common enterovirus that usually causes hand, foot and mouth disease in children but is often associated 
with brainstem encephalitis, neurogenic shock and polio-like acute flaccid paralysis. EV71 caused  
an outbreak with 78 mortalities in 1998, with manifestations of neurological involvement and 
cardiopulmonary failure. In a long-term study, survivors of EV71-induced CNS infection were found to 
have neurological sequelae and retarded mental development [3]. Several epidemics occurred and 
caused a total of 51 fatalities in 2000–2001 [4]. Unfortunately, there is no therapy with proven efficacy 
to control EV71. Given these recurring outbreaks and annual epidemics, there is a clear need to develop 
inhibitors for EV71. 
Viruses must deliver their genome into the host cells to initiate replication. Most of them enter  
cells by endocytosis during which they hijack cellular machinery for the attachment to receptors and 
subsequent penetration across the plasma membrane. Several receptors to facilitate EV71 entry have 
been reported, including scavenger receptor B2, human P-selectin glycoprotein ligand-1 and sialylated 
glycans [5–7]. A strategy to disrupt the interaction between viral particles and their receptors would be 
ideal for antiviral development. 
We have been identifying traditional Chinese medicines with antiviral or prophylactic activity against 
EV71 infections [8,9]. The flower buds of Daphne genkwa Sieb. et Zucc. (Thymelaeaceae), known as 
Won-Hwa or Yuanhua in Chinese, are collected in the spring before blossoming. As a traditional 
medicine, they have been used as an abortifacient [10], with purgative, diuretic and anti-inflammatory 
actions [11]. Previous phytochemical studies on D. genkwa have led to the isolation of 
pharmacologically active flavonoids, diterpene orthoesters and coumarins, showing inhibitory activity 
against xanthine oxidase and adenosine 3,5-cyclic monophosphate phosphodiesterase, as well as 
exhibiting antileukemic activity [12]. In the present study, we used Chinese traditional medicine 
extracts for anti-EV71 activity. We found that Daphne genkwa Sieb. et Zucc. extracts (DGFW) could 
neutralize the EV71-induced cytopathic effect (CPE) in human embryonic rhabdomyosarcoma (RD) 
cells. The  half maximal effective concentration (EC50) of DGFW on EV71 was approximately  
0.163 ± 0.013 mg/mL. DGFW inhibited EV71 viral protein and viral RNA synthesis. Additionally, 
DGFW suppressed viral activity at the adsorption stage of uptake as shown by a time-of-addition assay. 
Cells pretreated with DGFW could not block viral infection. Therefore, it is possible that DGFW binds 
to the virus to affect its activity. We conclude that DGFW possesses antiviral activity and has the 
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2. Results and Discussion 
2.1. The Water-Soluble Fraction of D. genkwa Inhibits Viral Replication 
In an endeavor to identify anti-EV71 Chinese medicines, we initially screened a panel of 48 extracts 
of Chinese herbs with antioxidant properties. An assay to measure the inhibition of virus-induced cell 
death in RD cells was first employed using 1 mg/mL of herbal extracts followed by EC50 determination if 
the candidates possessed antiviral activity from the primary screening. We identified that the water 
fraction of D. genkwa was a potent agent against EV71 isolate 2231 with an EC50 of 0.163 ± 0.013 mg/mL 
and a concentration producing 50% cytotoxicity (CC50) of 1.444 ± 0.193 mg/mL using RD cells (Table 1). 
However, its solvent (CHCl3) layer did not demonstrate anti-EV71 activity (Figure 1). DGFW was also 
able to inhibit successfully other isolates of EV71 except for isolate 1101 (genotype B5; Table 1). 
Interestingly, this extract was effective against influenza virus, although the selectivity index was not 
satisfactory. However, DGFW did not show activity against CVs or two DNA viruses, adenovirus and 
HSV-1, at a concentration of 1 mg/mL (Table 1). 
Table 1. Viral inhibition spectrum of D. genkwa Sieb. et Zucc. (DGFW). 
Title 
Concentration (mg/mL) 
CC50 
a EC50 
b SI 
c 
Cytotoxic effect       
RD cells  1.444 ± 0.193     
MDCK cells  1.603 ± 0.091     
HFF3 cells  2.354 ± 0.018     
A549 cells  >2     
EV71
d, TW/2231/98 (genotype C)    0.163 ± 0.013  8.859 
EV71, BrCr (genotype A)    0.182 ± 0.027  7.934 
EV71, TW/71552/05 (subgenotype C4)    0.824 ± 0.004  1.752 
EV71, TW/1101/08 (subgenotype B5)    >1  – 
CV-B1 
d     >1  – 
CV-B2   >1  – 
CV-B3     >1  – 
CV-B4     >1  – 
CV-B5     >1  – 
Influenza virus A/WSN/33      0.838 ± 0.026  1.913 
Adenovirus   >2  – 
HSV-1 
d   >2  – 
a CC50 was determined by MTT assay; 
b EC50 was determined by inhibiting the virus-induced CPE. 
Different isolates of enterovirus (EV)71 and coxsackieviruses (CV) were assayed in RD cells; 
adenovirus and HSV-1 were assayed in A549 cells; and influenza virus was assayed in MDCK cells; 
c SI (selectivity index) is the ratio of CC50 to EC50; 
d EV71: enterovirus 71; CV: Coxsackievirus; 
HSV, herpes simplex virus. Viruses 2012, 4  542 
 
Figure 1. Flow chart of preparation of water-soluble fractions of D. genkwa. 
 
The preparation of DGFW is shown in Figure 1 and the final dried extract was weighed and dissolved 
in DMSO for antiviral analysis. We explored the effects of DGFW in protecting against virus-induced 
CPE on RD cells by microscopic assay (Figure 2). The RD cells were infected with EV71 isolate 2231 in 
the presence or absence of 0.5 mg/mL, which was not toxic to the cells by MTT assay (Figure S1). RD 
cells infected with virus displayed a typical CPE in which the cells became rounded and eventually 
detached from the culture dish (panel D, Figure 2). This effect was not caused by DGFW alone (panel B, 
Figure 2) or 0.25% vehicle DMSO (panel C, Figure 2). DGFW but not DMSO protected the cells from 
virus-induced CPE (panel E versus F, Figure 2), indicating that DGFW inhibited viral replication. We 
therefore performed qPCR and western blotting to confirm the antiviral effect of DGFW (Figure 3). The 
cells were first infected with virus in the presence or absence of DGFW and the cells were harvested at 
indicated points (Figure 3A). The amount of viral RNA was quantified against a standard curve of 
known concentrations. The synthesis of viral protein was measured as viral proteins 3A and 3C. DGFW 
substantially reduced the synthesis of viral RNA and viral proteins (Figure 3B,C). Viruses 2012, 4  543 
 
Figure 2. Inhibition of enterovirus 71 (EV71)-induced cytopathic effect (CPE) by DGFW. 
rhabdomyosarcoma (RD) cells were preadsorbed with EV71 (m.o.i. 1) in the presence or 
absence of 0.5 mg/mL DGFW for 1 h at 4 °C. The culture medium was removed and 
replaced with DMEM containing 2% FBS with or without DGFW. After 20 h, the cells were 
fixed and stained with SRB, followed by microscopy. (A) Mock; (B) Mock + 0.5 mg/mL;   
(C) Mock + 0.25% DMSO; (D) Virus; (E) Virus + 0.5 mg/mL DGFW; (F) Virus + 0.25% 
DMSO. 
(A) (B) 
(C) (D) 
(E) (F) Viruses 2012, 4  544 
 
Figure 3. DGFW inhibits viral protein and RNA synthesis. (A) An illustration of the 
treatment with DGFW. Cells were preadsorbed with EV71 at an m.o.i. of 5 in the presence 
of 0.5 mg/mL DGFW. Culture supernatants were then replaced with DMEM containing 
2% FBS and DGFW. The cells were preadsorbed with virus at 4 °C between −1 to 0 h p.i. 
The cells were then harvested at 0, 3, 6 and 9 h p.i. for qPCR (B) and western blot (C) 
analysis. The quantity of viral RNA was quantified against a standard curve of a serial 
dilution of viral RNA. M and D indicate mock-infected cells and drug-treated cells, 
respectively. These are representative data from three independent experiments. The data 
were analyzed using two-tailed Student’s t-tests and are expressed as the mean ± SEM.  
* p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
(A) 
 
(B) 
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2.2. DGFW Inhibits Early Stages of Replication 
We assessed the antiviral mode of action using a time-of-addition assay in which DGFW was added 
at different stages of one infection cycle (Figure 4). DGFW was either added before viral preadsorption, 
during adsorption (–1 to 0 h p.i.), or after viral adsorption. The viruses from cells and culture medium 
were then collected for plaque assay at 10 h p.i. (Figure 4B). DGFW was able to reduce viral titer 
considerably during the viral preadsorption step between −1 and 0 h p.i. (lane 4, Figure 4). DGFW did 
not target the cells when it was added before viral preadsorption (lanes 1–3, Figure 4B). The late stages, 
such as viral package and release, were not inhibited by DGFW because no reduction of viral titer was 
seen when the extract was added immediately after viral adsorption (lanes 6–8, Figure 4B). Altogether, 
these results demonstrate that DGFW might target cellular uptake of the virus. 
Figure 4. Time-of-addition assay of DGFW. (a) RD cells were infected with EV71 (m.o.i. 5). 
DGFW (0.5 mg/mL) was added at the designated times. (b) Viral adsorption was from −1 to 
0 h p.i. on ice. DGFW (0.5 mg/mL in E2) was added to the cells at the indicated times. After 
each treatment, DGFW was washed and replaced with fresh E2. RD cells were pretreated 
with DGFW from −9 to −1, −6 to −1, or −3 to −1 h p.i. The cells were washed and inoculated 
with EV71 for 1 h, and the unbound virus was removed and replaced with E2 and incubated 
for an additional 10 h. The supernatants were collected and the viral yields determined by 
plaque assay; “virus” is a virus-only control without DGFW treatment. The ratio of viral 
titers is presented as the mean ± SEM of the results of two experiments, and this is 
normalized to the virus-only control, set to 1. This is one representative result from two 
independent experiments. 
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Figure 4. Cont. 
 
(B) 
2.3. DGFW Inhibits Viral Attachment and Penetration 
To test the mechanism of inhibition of viral entry into host cells by DGFW, we performed 
attachment and penetration assays. Viral uptake into cells occurs first by binding to receptors followed 
by clathrin-dependent endocytosis into early endosomes [13]. The attachment assay was used to 
examine the binding of the virus to receptors, and the penetration assay was used to test the entry step 
following receptor binding. We used HFF3 cells for these assays because RD cells were easily 
detached from the dishes when incubated on ice, and HFF3 cells are susceptible to EV71 infection 
[14]. For the attachment assay, the HFF3 cells were incubated with 100 TCID50 of EV71 for 3 h in the 
presence of DGFW on ice. The cytoprotection of DGFW was then determined. DGFW was able to 
inhibit attachment of EV71 into HFF3 cells with an EC50 of 0.185 ± 0.056 mg/mL (Figure 5A). For the 
penetration assay, DGFW was added during viral entry into cells at 37 °C following viral preadsorption. 
DGFW was also able to inhibit penetration with an IC50 of 0.245 ± 0.063 mg/mL (Figure 5B). DGFW 
might bind to and thus inhibit the virus, because DGFW displayed a similar IC50 against EV71 based on 
attachment and penetration assays. Viruses 2012, 4  547 
 
Figure 5. Inhibition of viral entry by DGFW. Human foreskin fibroblast (HFF3) cells were 
cultured in 96-well plates. Cytoprotection was then measured by crystal violet staining of 
the attached cells on the plates. A Pueraria lobata extract at 3.125 mg/mL served as a 
positive control. (A) Dose dependence of DGFW inhibition of EV71 attachment. Increasing 
concentrations of DGFW were added to cells infected with EV71 and incubated for 3 h on 
ice. The cells were washed with DPBS and replaced with E2, warmed to 37 °C and incubated 
for 72 h. Cytoprotection was then determined. (B) Dose dependence of DGFW inhibition of 
EV71 penetration. HFF3 cells were chilled on ice for 1 h, followed by preadsorption of 
EV71 for 3 h on ice. Increasing concentrations of DGFW were then added, warmed to 37 °C 
and incubated for 1 h to allow the virus to enter the cells. The monolayers were treated with 
alkaline PBS (pH 11) to inactivate extracellular virus and were incubated at 37 °C for 72 h. 
Cytoprotection was then determined. This is a representative result from three independent 
experiments. 
(A) (B) 
2.4. DGFW Targets the Virus Directly but not the Host Cells 
We next examined whether DGFW acted at the cell surface, such as via receptor–virus binding, by 
pretreatment of RD cells with DGFW for 30 min at 37 °C (lane 2, Figure 6). Unbound DGFW was 
removed, the cells were then infected with EV71 for 1 h, and the progeny viruses in the cells and 
culture medium were harvested for plaque assay at 10 h p.i. Similarly, EV71 was pretreated with 
DGFW or DMSO for 30 min at 37 °C, and the infectivity of the treated virus was then determined by 
plaque assay (Figure 6). Pretreatment of cells with DGFW did not show any reduction of viral titer, 
suggesting that DGFW did not affect viral binding to the cells directly. In contrast, pretreatment of the 
virus with DGFW caused a substantial reduction of viral titer, but this was not seen after treatment 
with DMSO alone, implying that DGFW might target the virus directly and specifically (Figure 6;  
lane 3 versus lane 4). This result was consistent with the time-of-addition assay (Figure 4). This direct 
targeting effect was further demonstrated by a lower concentration of DGFW. This was done by 
pretreating the virus with DGFW for 30 min followed by diluting the mixture 10
5-fold, whereby the Viruses 2012, 4  548 
 
DGFW did not have inhibitory activity. The infectivity of the treated virus was then determined by 
plaque assay (Figure 6B). Pretreatment with DGFW produced a significant reduction of viral titer by 
about 50% compared with the DMSO control, suggesting again that DGFW suppresses viral activity 
by targeting the virus directly (Figure 6B). 
Figure 6. DGFW might target the virus directly. (A) EV71 (m.o.i. 5) was preincubated 
with DGFW (0.5 mg/mL) or control vehicle (DMSO) for 30 min at 37 °C (−1.5 to −1 h. 
p.i.) and was then used to inoculate RD cells for 1 h (adsorption at −1 to 0 h p.i.). 
Similarly, RD cells were pretreated with DGFW for 30 min before viral adsorption for 1 h 
(–1 to 0 h p.i.). At 10 h p.i., the cells and culture medium were pooled for the determination 
of viral titers by plaque assays. “All” indicates the presence of DGFW all through from −1.5 
to 10 h p.i.; “virus” is a nontreated virus control, and the titer was set to 1. The fold change 
of viral titers is presented as the mean ± SEM of the results of two independent experiments.  
** p < 0.01; (B) EV71 was preincubated with DGFW (1 mg/mL) or DMSO for 30 min at 37 
°C. The mixture was diluted 10
5-fold for the plaque assay. The viral titer from pretreatment 
with DMSO was set to 1, and the fold change of viral titers is presented as the mean ± SEM 
of the results of two independent experiments. ** p < 0.01. 
(A) (B) 
2.5. Discussion 
In this study, we demonstrated that DGFW suppressed viral adsorption to RD cells by time-of-addition 
assay. Cells pretreated with DGFW did not show inhibition of viral infection, indicating that DGFW does Viruses 2012, 4  549 
 
not inhibit cellular viral receptors. However, DGFW was able to inhibit viral endocytosis by reducing viral 
attachment to and penetration into host cells. Furthermore, pretreatment of virus with DGFW abolished 
viral replication, indicating that DGFW inhibits EV71 by targeting the virus directly (Figure 6). 
Currently, there is no effective vaccine or antiviral agent to combat EV71. Many antienteroviral 
agents against poliovirus or rhinovirus have been thus tested for their efficacy against EV71. Pleconaril, 
a WIN compound and in clinical development, has been reported to inhibit several types of 
enterovirus-induced meningitis and aseptic meningitis [15]. The WIN series of compounds inhibit viral 
replication primarily by binding the hydrophobic canyon region of capsid protein VP1 to stabilize  
the viral capsid structure, so that after the virus enters the host cell it cannot undergo the uncoating 
process [16]. However, Pleconaril did not effectively inhibit the CPE induced in cell cultures by the 
EV71 strain isolated from patients who had contracted hand, foot and mouth disease in 1998 [17]. We 
demonstrated here that DGFW might target the viral particle for inhibition. However, DGFW did not 
show strong binding activity to the virus in a filter assay, suggesting that DGFW acts through transient 
binding but leads on to potent inhibitory activity (Figure S2). 
Phylogenetic analysis of complete VP1 sequences has identified three EV71 genotypes: A, B and C. 
Genotypes B and C can be further divided into subgenotypes B1 to B5 and C1 to C5 [18]. DGFW 
inhibited EV71/BrCr, EV71/TW/2231/98 and EV71/TW/71552/05, which belong to subgenotypes A, 
C2 and C4, respectively. However, the EC50 of DGFW against EV71/TW/1101/08 (subgenotype B5) 
was greater than 1 mg/mL, but this dose was equivalent to the effective cytotoxic concentration and 
therefore cannot be considered as having an inhibitory effect. We demonstrated that DGFW targets the 
virus to inhibit the attachment and entry steps. However, DGFW did not inhibit the B5 subgenotype, and 
this can be explained by the demonstrated differences in VP1 sequences [19]. The phylogenetic analysis 
showed distinct differences between CV-B and EV71, and consequently DGFW did not inhibit CV-B1 
to B5 as expected (Table 1). Additionally, as DGFW appears to inhibit different genotypes of EV71 to 
different degrees, this might explain why DGFW does not target cellular factor(s). 
Flavonoids are common constituents of plants used in traditional Chinese medicine to treat a variety 
of diseases. D. genkwa has been used for the isolation of flavonoids, and studies have reported the 
isolation of luteolin, 7-O-methylluteolin, tiliroside [20], apigenin, genkwanin, sitosterol, benzoic  
acid [21] and genkwadaphnin [21,22] from the dried flower buds. Apigenin showed a strong inhibitory 
activity against xanthine oxidase [21], as well as against severe acute respiratory syndrome coronavirus 
(SARS-CoV) and influenza virus [23–25]. Luteolin and its glycosides have been widely used for their 
antimicrobial properties, and HBV, SARS-CoV and the influenza virus can be inhibited as shown by in 
vitro studies [24–26]. However, no anti-EV71 activity of flavonoids isolated from D. genkwa has been 
demonstrated. Interestingly, similar to our findings, apigenin was able to inhibit the influenza virus but 
did not show antiviral activity against HSV (Table 1) [23,24,27]. The examination of anti-EV71 
activities of apigenin and other purified compounds from D. genkwa is ongoing. On a cautionary note, 
Daphne bud extracts, whether from the ether layer or the water layer, can also induce early antigen 
expression of Epstein–Barr virus (EBV) [28]. Up to 90% of the world’s human population has a latent 
EBV infection, and it has a high association with nasopharyngeal carcinomas in southeast Asia and 
certain other countries [29]. In addition, D. genkwa possesses the harmful side effect of abortifacient 
activity. Thus, there is a need to isolate the effective anti-EV71 ingredients that do not lead to the 
induction of EBV early antigen production or act as abortifacients. Viruses 2012, 4  550 
 
3. Experimental Section 
3.1. Virus and Cell Culture and Viral Amplification 
RD cells and human foreskin fibroblast (HFF3) cells were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Life 
Technologies, Grand Island, NY, USA). Madin–Darby canine kidney (MDCK) cells were cultured in 
DMEM plus 10% FBS, 2 mM L-glutamine (Gibco) and 0.1 mM nonessential amino acids (NEAA; 
BioWhittaker Inc., Walkersville, MD, USA). Adenocarcinomic human alveolar basal epithelial cells 
(A549) were cultured in MEM containing NEAA. All cells were kept at 37 °C under 5% CO2 in air in 
a humid incubator. EV71 TW/2231/98 (genotype C), BrCr (genotype A), TW/71552/05 (subgenotype 
C4), TW/1101/08 (subgenotype B5), coxsackievirus (CV)-B1 to B5, herpes simplex virus (HSV)-1 
and adenoviruses were kindly supplied from the Clinical Virology Laboratory of Chang Gung 
Memorial Hospital, Taiwan (Table 1) [30]. Influenza virus A/WSN/33 was obtained from the 
American Type Cell Culture and was amplified accordingly [30]. Overnight cultures of monolayers of 
RD cells were washed with Dulbecco’s phosphate-buffered saline (DPBS) before being inoculated 
with EV71 or CV-B at a multiplicity of infection (m.o.i.) of 0.01. The cells and culture supernatants 
containing viral progeny were collected when cells developed a CPE of ~80%. The progeny viruses 
inside the cells were released by three cycles of freezing–thawing, and the resulting viral suspension 
was pooled with the culture medium, aliquoted and stored at −80 °C until use. 
3.2. Plant Material 
Dry flower buds of Daphne genkwa were supplied and authenticated by the Department of Pharmacy, 
Chang Gung Memorial Hospital at Chiayi, Taiwan. A voucher specimen (No. CGU-DG-1) was deposited 
in the herbarium of Chang Gung University, Taoyuan, Taiwan. Dry flower buds (5.0 kg) were extracted 
with methanol seven times (30 L each) under reflux for 8 h and concentrated to give a brown syrup  
(745.75 g) (Figure 1). The syrup was suspended in H2O and partitioned with CHCl3 and n-butanol, 
successively. The water-soluble layer was concentrated to gain a red-brown syrup (153.27 g). 
3.3. Determination of Median Tissue Culture Infective dose and Antiviral Neutralization Assay 
Monolayers of RD cells (2  10
4 per well) were cultured in 96-well plates overnight before use. EV71 
TW/2231/98 was used hereafter if not mentioned otherwise. A virus suspension with threefold serial 
dilution in DMEM containing 2% FBS (E2) was added to the cells and incubated at 37 °C for 72 h and 
subsequently fixed with 100 L of 4% paraformaldehyde (PFA) for 2 h. The attached cells were stained 
with 0.1% crystal violet at room temperature, and the density of staining was measured in a microplate 
reader (Dynex Technologies, Chantilly, VA, USA). The dilution causing cytopathology in half the cultures 
(the median tissue culture infective dose, or TCID50) was then calculated using the Reed–Muench 
method. The TCID50 determinations for the attachment and penetration assays were performed similarly 
except that preadsorption was carried out for 3 h on ice. A neutralization assay (EC50) was used to  
test the antiviral efficacy of extracts or compounds by measuring the inhibition of CPE induced by 
enterovirus on RD cells. RD cells (2  10
4 cells/well) were seeded into 96-well plates and incubated Viruses 2012, 4  551 
 
for 16–20 h at 37 °C in a 5% CO2/air incubator. After infection, cells were overlaid with 50 L of 
different concentrations of extracts and incubated at 37 °C in a 5% CO2/air incubator for 72 h. At the end 
of incubation, cells were fixed with PFA, followed by 0.1% crystal violet staining. The concentration 
required for extracts to reduce the virus-induced CPE by 50% relative to the virus control was defined as 
the EC50. 
3.4. Cytotoxicity Assay 
Aliquots of 2  10
4 RD cells per well were seeded overnight in 96-well plates before use. Twofold 
serial dilutions of DGFW in E2 were added and incubated at 37 °C for 72 h. The medium was carefully 
withdrawn without touching the cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium 
bromide; 0.5 mg/mL, Sigma-Aldrich, St Louis, MO, USA) was added at 50 L/well and incubated for 
3 h. Dimethylsulfoxide (DMSO; 200 L/well) was added to dissolve the crystals, and the absorbance 
at 570 nm of each well was measured using a microtiter plate reader (MRX ELISA reader, Dynex 
Technologies). The concentration of DGFW that caused the death of 50% of the cells was defined as the 
50% cytotoxic concentration (CC50). 
3.5. Plaque Assay 
Monolayers of RD cells (4.5  10
5 per well) were seeded in 6-well plates. After an 18 h culture, the 
cells were inoculated with serially diluted viral suspensions for 1 h. The cells were washed with DPBS 
and overlaid with warm 0.3% agarose in E2. After incubation for 4 days, the cells were fixed with 4% 
PFA for 2 h. The agarose was carefully removed and subsequently stained with 0.1% crystal violet. 
The titer of the virus was expressed as plaque-forming units (PFU) per mL. 
3.6. Western Blotting 
After electrophoresis, proteins were electrotransferred onto polyvinylidene fluoride membranes 
(Millipore, Billerica, MA, USA). The proteins of interest were incubated with primary antibodies for 1 h 
and then incubated with appropriate secondary antibodies. Proteins were detected by using an enhanced 
chemiluminescence western blotting detection system (Millipore). Polyclonal antibodies against 3A and 
a monoclonal antibody against 3C were as described [31,32]. 
3.7. CPE Testing 
RD cells (4  10
5 cells/mL) were seeded into 6-well plates and then challenged with viruses at an 
m.o.i. of 1. The cells were pretreated with viruses for 1 h on ice and washed with DPBS, and then E2 
was added. After 20 h incubation at 37 °C, the cells were stained with 0.4% sulforhodamine B (SRB) 
in 1% acetic acid, and CPE was observed using a microscope. For DGFW treatment, the cells were 
pretreated with 0.5 mg/mL extracts and virus simultaneously for 1 h and washed with DPBS, and then 
E2 containing 0.5 mg/mL DGFW was added. The protective effect exerted by DGFW  was also 
observed after incubation for 20 h at 37 °C. Viruses 2012, 4  552 
 
3.8. Reverse Transcription Polymerase Chain Reaction (PCR) Amplification and Absolute  
Quantitative (q)PCR 
The in vitro transcripts of the EV71/2231 infectious clone plasmid, which was kindly provided by Dr. 
Meishan Ho of Academia Sinica, Taiwan, was serially diluted tenfold for spectrophotometric analysis. 
After determining the RNA concentration, the copy number of standard RNA molecules can be calculated 
using the following formula: (X g/L RNA /[transcript length in nucleotides  340])  6.022  1023 =  
Y molecules/L. The viral RNA was then mixed with 50 nM forward and reverse primers and SYBR 
green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) followed by qPCR analysis using 
an ABI StepOne Plus Sequence Detector System (Applied Biosystems). The primers used were: EV71 
VP2 forward, 5–CTG ATG GCT TCG AAT TGC AA–3, and reverse, 5–GCG TTT ATG TAC GGC 
ACT ATT ATT GT–3; GAPDH forward, 5–GGT GGT CTC CTC TGA CTT CAA CA–3, and 
reverse, 5–GCG TCA AAG GTG GAG GAG TG–3. A standard curve (plot of the CT value/crossing 
point against the log of the amount of standard added) was thus generated using different dilutions of the 
standard. RD cells (4  10
5 cells/well) were seeded in 6-well plates overnight. The cells were then 
preadsorbed with EV71 at an m.o.i. of 5 for 1 h in the presence of 0.5 mg/mL DGFW. The culture 
medium was then replaced with E2 containing the same concentration of DGFW, and the cells were 
incubated at 37 °C and harvested at 0, 3, 6 and 9 h post infection (p.i.) for total RNA extraction using 
TRIzol. cDNA was prepared by reverse transcription with M-MLV RT kits (Invitrogen, Carlsbad, CA, 
USA) for qPCR analysis using specific viral primers: forward, 5–CTG ATG GCT TCG AAT TGC 
AA–3, and reverse, 5–GCG TTT ATG TAC GGC ACT ATT ATT GT–3. Amplification was 
achieved using the following universal thermal cycling protocol: one cycle at 95 °C for 15 min, 40 cycles 
at 95 °C for 15 s and 60 °C for 1 min. The absolute amounts of viral RNA were then determined using an 
external standard curve. 
3.9. Time-of-Addition Assay 
A 6-well tissue culture plate was seeded with RD cells (4  10
5 cells/well), and incubated at 37 °C for 
16–20 h under 5% CO2 in air. The cells were infected with EV71 at an m.o.i. of 5 on ice. After viral 
adsorption, the cells were washed with Hank’s buffered salt solution to remove any unbound virus. 
DGFW (0.5 mg/mL) in E2 was added at −9 to −1 h, −6 to −1 h and −3 to −1 h (preadsorption), −1 to 0 h 
(adsorption), 0 to 10 h, 3 to 10 h and 6 to 10 h (postadsorption). The supernatants were harvested at 10 h 
p.i., and the viral titers were determined by plaque-forming assays. 
3.10. Attachment Assay 
A 96-well tissue culture plate was seeded with HFF3 cells (2  10
4 cells/well), which were then 
incubated overnight at 37 °C under 5% CO2 in air. The cells were chilled on ice for 1 h, and the medium 
was removed. The cells were infected with 100 TCID50 of EV71 in the presence of increasing 
concentrations of DGFW on ice for 3 h. The medium containing the unadsorbed virus was removed, and 
the cells were then washed three times with DPBS. After incubation for 72 h in E2 at 37 °C, cells were 
fixed with 4% PFA and stained with crystal violet. Cell viability was determined by measuring the cell Viruses 2012, 4  553 
 
density in a microplate reader (MRX ELISA reader, Dynex Technologies). A Pueraria lobata extract at 
3.125 mg/mL served as a positive control [33]. This attachment method has been described [34]. 
3.11. Penetration Assay 
A 96-well tissue culture plate was seeded with HFF3 cells (2  10
4 cells/well), which were then 
incubated overnight at 37 °C under 5% CO2. The cells were chilled on ice for 1 h, and the medium was 
removed. The cells were infected with 100 TCID50 of EV71 on ice for 3 h. The medium containing 
unbound virus was then removed; various concentrations of DGFW in E2 were added, and the cells  
were incubated at 37 °C for 1 h to trigger endocytosis of the virus. The infected cells were then treated  
with alkaline phosphate-buffered saline (PBS; pH 11) for 1 min to inactivate any viruses that had not 
penetrated the cells, and then acidic PBS (pH 3) was immediately added to neutralize the mix. The 
neutralized medium was removed, E2 was then replaced, and the cells were incubated at 37 °C for 72 h. 
The cells were fixed with PFA and subjected to 0.1% crystal violet staining. A Pueraria lobata extract 
at 3.125 mg/mL served as a positive control [33]. This penetration assay was modified from previous 
reports [35,36]. 
3.12. Data Analysis 
Data are expressed as the mean ± standard error of the mean [37] and analyzed using two-tailed 
Student’s t-tests with p < 0.05 taken as significant. 
4. Conclusions 
GFW exerts its anti-EV71 effects by inhibiting viral entry without producing cytotoxic side effects 
and thus provides a potential agent for antiviral chemotherapeutics. 
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